Soft Tissue Sarcoma

Oncology
27
Pipeline Programs
17
Companies
50
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
1
14
1
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
556%
Small Molecule
444%
+ 22 programs with unclassified modality

Competitive Landscape

17 companies ranked by most advanced pipeline stage

CT
4 programs
2
1
1
Anlotinib hydrochloride capsulePhase 31 trial
AnlotinibPhase 2/3Small Molecule1 trial
Anlotinib HydrochloridePhase 21 trial
TQB2916 injection + doxorubicin hydrochloride for injectionPhase 21 trial
Active Trials
NCT03890068UnknownEst. May 2024
NCT06500091Not Yet RecruitingEst. Dec 2026
NCT02449343UnknownEst. Apr 2017
+1 more trials
Philogen
PhilogenItaly - Monteriggioni
3 programs
1
1
1
Onfekafusp alfaPhase 31 trial
DacarbazinePhase 21 trial
L19TNFPhase 11 trial
Active Trials
NCT04032964Active Not Recruiting2Est. Dec 2024
NCT04733183Active Not Recruiting98Est. Dec 2025
NCT04650984Recruiting102Est. Dec 2025
E
EisaiChina - Liaoning
3 programs
2
1
Eribulin mesylate 1.4 mg/m^2 intravenousPhase 31 trial
E7389Phase 21 trial
eribulin mesylatePhase 21 trial
Active Trials
NCT00413192Completed128Est. Feb 2013
NCT01458249Completed52Est. Feb 2016
NCT01327885Completed452Est. Aug 2016
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
3 programs
2
EIA chemotherapyPhase 21 trial
VorinostatPhase 2Small Molecule1 trial
ProtonsN/A1 trial
Active Trials
NCT04946357Recruiting42Est. Jul 2026
NCT01382030Completed50Est. Jan 2011
NCT00918489Completed40Est. Sep 2013
Alliance Pharmaceuticals
2 programs
1
PembrolizumabPhase 2Monoclonal Antibody4 trials
Th-302N/A1 trial
Active Trials
NCT02712567No Longer Available
NCT05273554Active Not Recruiting15Est. Dec 2027
NCT03092323Active Not Recruiting126Est. Sep 2028
+2 more trials
M&
Merck & Co.RAHWAY, NJ
2 programs
1
1
TH-302Phase 21 trial
OlaratumabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT03126591Completed41Est. Feb 2023
NCT02255110TerminatedEst. Jan 2016
Precision BioSciences
2 programs
1
1
NY-ESO-1Phase 21 trial
TAEST16001 cellsPhase 11 trial
Active Trials
NCT04318964Unknown12Est. May 2024
NCT05549921Unknown70Est. Sep 2024
Genentech
GenentechCA - Oceanside
1 program
1
AtezolizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT07049848Recruiting50Est. Jan 2030
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
1
ChiauranibPhase 2Small Molecule1 trial
Active Trials
NCT05497843CompletedEst. Jan 2025
AT
Actuate TherapeuticsFORT WORTH, TX
1 program
1
GemcitabinePhase 21 trial
Active Trials
NCT05116800WithdrawnEst. Aug 2030
Amgen
AmgenTHOUSAND OAKS, CA
1 program
1
Talimogene LaherparepvecPhase 25 trials
Active Trials
NCT02147951No Longer Available
NCT06660810Active Not Recruiting2Est. Mar 2030
NCT04599062Active Not Recruiting8Est. Feb 2028
+2 more trials
Bayer
BayerLEVERKUSEN, Germany
1 program
1
SorafenibPhase 1/2Small Molecule1 trial
Active Trials
NCT00864032Completed8Est. Aug 2011
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
OlaratumabPhase 1Monoclonal Antibody3 trials
OlaratumabN/AMonoclonal Antibody1 trial
Active Trials
NCT03994627Approved For Marketing
NCT01316263Terminated21Est. Nov 2012
NCT01199822Completed16Est. Jan 2012
+1 more trials
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
2 programs
1
DoxorubicinPhase 11 trial
TrabectedinN/A1 trial
Active Trials
NCT01427582No Longer Available
NCT00102609Completed41Est. Oct 2007
HiFiBiO Therapeutics
HiFiBiO TherapeuticsMA - Cambridge
1 program
1
HFB301001Phase 11 trial
Active Trials
NCT05229601TerminatedEst. May 2024
Pfizer
PfizerNEW YORK, NY
1 program
1
SGN-CD47MPhase 11 trial
Active Trials
NCT03957096Terminated16Est. Sep 2020
Karyopharm Therapeutics
1 program
1
SelinexorPhase 11 trial
Active Trials
NCT03042819CompletedEst. Jun 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Chia Tai TianQing Pharmaceutical GroupAnlotinib hydrochloride capsule
PhilogenOnfekafusp alfa
EisaiEribulin mesylate 1.4 mg/m^2 intravenous
AmgenTalimogene Laherparepvec
AmgenTalimogene Laherparepvec
Chia Tai TianQing Pharmaceutical GroupAnlotinib
GenentechAtezolizumab
AmgenTalimogene Laherparepvec
Chia Tai TianQing Pharmaceutical GroupTQB2916 injection + doxorubicin hydrochloride for injection
Chipscreen BiosciencesChiauranib
Precision BioSciencesNY-ESO-1
Actuate TherapeuticsGemcitabine
PhilogenDacarbazine
Chia Tai TianQing Pharmaceutical GroupAnlotinib Hydrochloride
Alliance PharmaceuticalsPembrolizumab

Showing 15 of 48 trials with date data

Clinical Trials (50)

Total enrollment: 2,745 patients across 50 trials

NCT05121350Chia Tai TianQing Pharmaceutical GroupAnlotinib hydrochloride capsule

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Start: Mar 2022Est. completion: Jun 2024
Phase 3Unknown
NCT04650984PhilogenOnfekafusp alfa

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Start: Nov 2017Est. completion: Dec 2025102 patients
Phase 3Recruiting
NCT01327885EisaiEribulin mesylate 1.4 mg/m^2 intravenous

Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Start: Mar 2011Est. completion: Aug 2016452 patients
Phase 3Completed
NCT01161498AmgenTalimogene Laherparepvec

Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer

Start: Feb 2011Est. completion: Oct 20115 patients
Phase 3Terminated
NCT00769704AmgenTalimogene Laherparepvec

Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma

Start: Apr 2009Est. completion: Sep 2014437 patients
Phase 3Completed
NCT02449343Chia Tai TianQing Pharmaceutical GroupAnlotinib

Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)

Start: May 2015Est. completion: Apr 2017
Phase 2/3Unknown
NCT07049848GenentechAtezolizumab

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

Start: Sep 2025Est. completion: Jan 203050 patients
Phase 2Recruiting
NCT06660810AmgenTalimogene Laherparepvec

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec

Start: Mar 2025Est. completion: Mar 20302 patients
Phase 2Active Not Recruiting
NCT06500091Chia Tai TianQing Pharmaceutical GroupTQB2916 injection + doxorubicin hydrochloride for injection

TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors

Start: Jul 2024Est. completion: Dec 2026
Phase 2Not Yet Recruiting
NCT05497843Chipscreen BiosciencesChiauranib

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Start: Aug 2022Est. completion: Jan 2025
Phase 2Completed
NCT05549921Precision BioSciencesNY-ESO-1

Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Start: Jul 2022Est. completion: Sep 202470 patients
Phase 2Unknown
NCT05116800Actuate TherapeuticsGemcitabine

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Start: Mar 2022Est. completion: Aug 2030
Phase 2Withdrawn
NCT04733183PhilogenDacarbazine

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Start: Aug 2020Est. completion: Dec 202598 patients
Phase 2Active Not Recruiting
NCT03890068Chia Tai TianQing Pharmaceutical GroupAnlotinib Hydrochloride

Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Start: Apr 2019Est. completion: May 2024
Phase 2Unknown
NCT03092323Alliance PharmaceuticalsPembrolizumab

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

Start: Jul 2017Est. completion: Sep 2028126 patients
Phase 2Active Not Recruiting
NCT02963090Alliance PharmaceuticalsPembrolizumab

Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer

Start: May 2017Est. completion: Aug 20199 patients
Phase 2Terminated
NCT02819843AmgenTalimogene Laherparepvec

A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

Start: Jun 2016Est. completion: Feb 202419 patients
Phase 2Completed
NCT02366195AmgenTalimogene Laherparepvec

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

Start: Apr 2015Est. completion: Dec 2020112 patients
Phase 2Completed
NCT02301039Alliance PharmaceuticalsPembrolizumab

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

Start: Mar 2015Est. completion: Jul 2020144 patients
Phase 2Completed
NCT02211131AmgenTalimogene Laherparepvec

Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma

Start: Feb 2015Est. completion: Apr 2022150 patients
Phase 2Completed
NCT02255110Merck & Co.TH-302

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Start: Dec 2014Est. completion: Jan 2016
Phase 2Terminated
NCT02014441AmgenTalimogene Laherparepvec

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Start: Apr 2014Est. completion: Apr 201861 patients
Phase 2Completed
NCT01458249Eisaieribulin mesylate

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Start: Nov 2011Est. completion: Feb 201652 patients
Phase 2Completed
NCT01316263Eli Lilly and CompanyOlaratumab

A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Start: Aug 2011Est. completion: Nov 201221 patients
Phase 2Terminated
NCT00895180Eli Lilly and CompanyOlaratumab

Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Start: Jul 2010Est. completion: Mar 201480 patients
Phase 2Completed
NCT00918489Heidelberg PharmaVorinostat

Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)

Start: May 2010Est. completion: Sep 201340 patients
Phase 2Completed
NCT00413192EisaiE7389

E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma

Start: Jan 2007Est. completion: Feb 2013128 patients
Phase 2Completed
NCT01382030Heidelberg PharmaEIA chemotherapy

Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma

Start: Jun 2005Est. completion: Jan 201150 patients
Phase 2Completed
NCT04599062AmgenTalimogene Laherparepvec

TVEC and Preop Radiation for Sarcoma (8 ml Dose)

Start: Sep 2020Est. completion: Feb 20288 patients
Phase 1/2Active Not Recruiting
NCT03597009AmgenTalimogene Laherparepvec

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

Start: Mar 2019Est. completion: Feb 20201 patients
Phase 1/2Terminated
NCT02779855AmgenTalimogene Laherparepvec

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Start: May 2017Est. completion: Aug 202550 patients
Phase 1/2Completed
NCT02453191AmgenTalimogene Laherparepvec

TVEC and Preop Radiation for Sarcoma (4 ml Dose)

Start: Jul 2015Est. completion: Mar 202330 patients
Phase 1/2Completed
NCT01740297AmgenTalimogene Laherparepvec

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Start: Feb 2013Est. completion: Mar 2021217 patients
Phase 1/2Completed
NCT00864032BayerSorafenib

Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall

Start: Mar 2009Est. completion: Aug 20118 patients
Phase 1/2Completed
NCT05273554Alliance PharmaceuticalsPembrolizumab

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Start: Aug 2022Est. completion: Dec 202715 patients
Phase 1Active Not Recruiting
NCT05229601HiFiBiO TherapeuticsHFB301001

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

Start: Apr 2022Est. completion: May 2024
Phase 1Terminated
NCT04318964Precision BioSciencesTAEST16001 cells

TAEST16001 in the Treatment of Soft Tissue Sarcoma

Start: Mar 2020Est. completion: May 202412 patients
Phase 1Unknown
NCT03554044AmgenTalimogene Laherparepvec

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer

Start: Feb 2020Est. completion: Dec 202320 patients
Phase 1Completed
NCT04032964PhilogenL19TNF

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

Start: Sep 2019Est. completion: Dec 20242 patients
Phase 1Active Not Recruiting
NCT03957096PfizerSGN-CD47M

A Safety Study of SGN-CD47M in Patients With Solid Tumors

Start: Jul 2019Est. completion: Sep 202016 patients
Phase 1Terminated
NCT03802604AmgenTalimogene Laherparepvec

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer

Start: Dec 2018Est. completion: Mar 202528 patients
Phase 1Completed
NCT03086642AmgenTalimogene Laherparepvec

Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer

Start: Nov 2017Est. completion: Dec 202210 patients
Phase 1Completed
NCT03126591Merck & Co.Olaratumab

A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Start: Jul 2017Est. completion: Feb 202341 patients
Phase 1Completed
NCT03088176AmgenTalimogene Laherparepvec

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Start: Jun 2017Est. completion: Jun 20214 patients
Phase 1Unknown
NCT03042819Karyopharm TherapeuticsSelinexor

Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas

Start: May 2017Est. completion: Jun 2021
Phase 1Completed
NCT03064763AmgenTalimogene Laherparepvec

Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma

Start: Mar 2017Est. completion: Jan 202318 patients
Phase 1Completed
NCT01199822Eli Lilly and CompanyOlaratumab

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

Start: Sep 2010Est. completion: Jan 201216 patients
Phase 1Completed
NCT00102609Johnson & JohnsonDoxorubicin

A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma

Start: Apr 2005Est. completion: Oct 200741 patients
Phase 1Completed
NCT02712567Alliance PharmaceuticalsTh-302

SARC021C: A Continuation Study of TH-CR-406/SARC021

N/ANo Longer Available
NCT01427582Johnson & JohnsonTrabectedin

YONDELIS (Trabectedin) Single Patient Compassionate Use / Expanded Access

N/ANo Longer Available

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1m ago

Office Administrator

SystImmune
1m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
12m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
15m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
15m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 2,745 patients
17 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)